Thus, the results of Marzesco et al. [53] and Lin et al. [54] along with our own observations warrant further studies of CD133 mRNA and/or protein in blood samples from pancreatic cancer patients. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.